September 25, 2026 (MLN): Macter International
Limited (PSX: MACTER) has launched Hepanox (Enoxaparin Sodium) in a Pre-filled
Syringe (PFS) format, adding a low molecular weight heparin (LMWH)
anticoagulant to its biopharmaceuticals portfolio.
Hepanox PFS is positioned as a low molecular weight heparin
anticoagulant.
The launch strengthens Macter’s presence in the anticoagulant
therapeutic segment and marks a milestone in expanding its biopharmaceuticals
portfolio, supporting the company’s long-term growth and its focus on
addressing evolving healthcare needs.
The aforementioned information was disseminated through a notification to
Exchange.
Copyright Mettis Link News